Ad
related to: biotech pharmaceuticals
Search results
The Zacks Analyst Blog Highlights Biogen, Ionis Pharmaceuticals, GSK, PTC Therapeutics and Larimar...
Zacks via Yahoo Finance· 5 days agoStocks recently featured in the blog include: Biogen BIIB, IonisPharmaceuticals IONS, GSK plc GSK,...
Merck Reportedly Nearing $1.3B Acquisition Of EyeBio To Expand Eye-Care Market Presence - Merck & Co...
Benzinga· 15 hours agoWhat Happened: The deal, which could be announced as early as Wednesday, will see Merck pay $1.3...
D.A. Davidson & CO. Has $1 Million Stock Holdings in Vertex Pharmaceuticals Incorporated...
ETF DAILY NEWS· 2 days agoD.A. Davidson & CO. decreased its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 26.9% in the 4th quarter, according to its most recent 13F filing ...
Cathie Wood's ARK buys AMD, sells Moderna in latest stock trades By Investing.com
Investing.com· 24 hours agoCathie Wood's ARK buys AMD, sells Moderna in latest stock trades
2 Stocks That Could 10x by 2035 | The Motley Fool
The Motley Fool· 6 days agoThere will be a slowdown, equities will fall, and many won't deliver anything approaching decent returns for years after. Viking Therapeutics is on a...
Quadrant Capital Group LLC Purchases 1,330 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
ETF DAILY NEWS· 2 days agoQuadrant Capital Group LLC lifted its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 1,117.6% in the 4th quarter, Holdings Channel reports ...
Biotech Stock Roundup: BIIB's Acquisition, PTCT, LRMR Gain on Updates & More News
Zacks· 7 days agoWith the end of the first-quarter earnings season, the focus has now shifted to pipeline and regulatory updates. Mergers and acquisitions continue to be in the spotlight as pharma and
Activation Capital Introduces 'Frontier BioHealth' to Catalyze Life Science Startups
FOX 59 Indianapolis· 6 days agoIt will broaden the continuum of regional early-stage support – additive to Virginia Commonwealth...
TD Cowen expects Medpace to 'outpace large pharma', initiates buy rating on stock By Investing.com
Investing.com· 11 hours agoThe firm assigned a Buy rating to Medpace, accompanied by a price target of $452.00. The coverage...
BMS stakes $80m on Prothena’s neurodegenerative candidate
Pharmaceutical Technology via Yahoo Finance· 11 hours agoThe biotech cited higher R&D and G&A expenses in 2023 compared to the previous year. Prothena’s most...
